Technical Analysis for NKTR - Nektar Therapeutics

Grade Last Price % Change Price Change
grade C 58.33 0.03% 0.02
NKTR closed up 0.03 percent on Tuesday, September 18, 2018, on 81 percent of normal volume. It was able to find support at its 50 day moving average. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Down
See historical NKTR trend table...

Date Alert Name Type % Chg
Sep 18 50 DMA Support Bullish 0.00%
Sep 18 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Sep 18 Lower Bollinger Band Walk Weakness 0.00%
Sep 18 Below Lower BB Weakness 0.00%
Sep 18 Lower Bollinger Band Touch Weakness 0.00%
Sep 18 Oversold Stochastic Weakness 0.00%
Sep 17 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.03%
Sep 17 Below Lower BB Weakness 0.03%
Sep 17 Down 3 Days in a Row Weakness 0.03%
Sep 17 Down 4 Days in a Row Weakness 0.03%

Older signals for NKTR ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Nektar Therapeutics, a clinical-stage biopharmaceutical company, engages in developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms. Its product pipeline consists of drug candidates in various therapeutic areas, including oncology, pain, anti-infectives, and immunology. The company's drug candidates in clinical development stage comprise naloxegol, an opioid antagonist that is in Phase 3 clinical trail for the treatment of opioid-induced constipation; BAY41-6551 that has completed Phase 2 clinical trail to treat gram-negative pneumonias; NKTR-181, a mu-opioid analgesic molecule, which is in Phase 2 clinical trail for chronic pain; and NKTR-192 that is in Phase 1 to treat acute pain. Its other product candidates comprise etirinotecan pegol, a topoisomerase I inhibitor, which is in Phase 3 clinical trial for the treatment of metastatic breast cancer; in Phase 2 clinical trail for ovarian cancer and second-line metastatic colorectal cancer; and in combination with 5-fluorouracil/leucovorin to treat metastatic colorectal cancer that completed Phase I clinical trial. In addition, the company offers preclinical drug candidates comprising opioid/NKTR-118 for the treatment of chronic pain; NKTR-171 to treat neuropathic pain; and NKTR-214, a cytokine immunostimulatory therapy for the treatment of oncology. Nektar Therapeutics has collaboration with Bayer Healthcare LLC to develop BAY41-6551 (NKTR-061, Amikacin Inhale), which is an inhaled solution of amikacin, an aminoglycoside antibiotic; and a license agreement with AstraZeneca AB for the development and commercialization of Oral NKTR-118 and NKTR-119. Further, it has various license, manufacturing, and supply agreements for its technology with biotechnology and pharmaceutical companies, such as Affymax, Amgen, MAP Pharmaceuticals, Merck, Pfizer, Roche, and UCB Pharma. The company was founded in 1990 and is headquartered in San Francisco, California.
Is NKTR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 111.36
52 Week Low 21.11
Average Volume 1,916,657
200-Day Moving Average 71.9395
50-Day Moving Average 57.3554
20-Day Moving Average 64.084
10-Day Moving Average 63.017
Average True Range 2.6767
ADX 29.67
+DI 15.0808
-DI 23.5974
Chandelier Exit (Long, 3 ATRs ) 61.7299
Chandelier Exit (Short, 3 ATRs ) 65.0601
Upper Bollinger Band 69.8516
Lower Bollinger Band 58.3164
Percent B (%b) 0.0
BandWidth 18.000125
MACD Line 0.3605
MACD Signal Line 1.7031
MACD Histogram -1.3426
Fundamentals Value
Market Cap 9.12 Billion
Num Shares 156 Million
EPS -1.40
Price-to-Earnings (P/E) Ratio -41.66
Price-to-Sales 27.79
Price-to-Book 1075.45
PEG Ratio 3.31
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 62.19
Resistance 3 (R3) 62.18 60.89 61.54
Resistance 2 (R2) 60.89 59.91 60.89 61.33
Resistance 1 (R1) 59.61 59.30 60.25 59.62 61.11
Pivot Point 58.32 58.32 58.64 58.32 58.32
Support 1 (S1) 57.04 57.34 57.68 57.05 55.55
Support 2 (S2) 55.75 56.73 55.75 55.33
Support 3 (S3) 54.47 55.75 55.12
Support 4 (S4) 54.48